Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$16.42

0.31% yesterday

NYSE, Aug 11, 10:10 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$16.42

+4.70 40.10% 5Y

NYSE, Closing price Mon, Aug 11 2025

+0.05 0.31%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$18.6b

Enterprise Value

$33.5b

Net debt

$15.0b

Cash

$1.7b

Shares outstanding

1.1b

Valuation (TTM | estimate)

P/E

negative | 6.3

P/S

1.1 | 1.1

EV/Sales

2.0 | 1.9

EV/FCF

43.8

P/B

3.0

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$16.6b | $17.4b

EBITDA

$4.7b | $5.0b

EBIT

$3.7b | $4.3b

Net Income

$-1.3b | $3.0b

Free Cash Flow

$766.0m

Growth (TTM | estimate)

Revenue

3.8% | 5.2%

EBITDA

-0.9% | 7.3%

EBIT

1.3% | 20.2%

Net Income

-160.9% | 280.2%

Free Cash Flow

-12.7%

Financial Health

Equity Ratio

13.7%

Return on Equity

-30.5%

ROCE

13.5%

ROIC

31.7%

Debt/Equity

2.7

EPS

$-1.1

FCF per Share

$0.7

Short interest

4.7%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

3x Hold

33%

6x Sell

67%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Hold

33%

Sell

67%

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	16,616 16,616	4% 4% 100%
- Direct Costs	8,227 8,227	4% 4% 50%
Gross Profit	8,389 8,389	4% 4% 50%
- Selling and Administrative Expenses	3,734 3,734	5% 5% 22%
- Research and Development Expense	1,003 1,003	4% 4% 6%
EBITDA	4,718 4,718	1% 1% 28%
- Depreciation and Amortization	1,031 1,031	8% 8% 6%
EBIT (Operating Income) EBIT	3,687 3,687	1% 1% 22%
Net Profit	-1,286 -1,286	161% 161% -8%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Positive

Reuters

●

6 days ago

US FDA approves Teva's Ajovy for migraine prevention in children

The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help prevent migraines in children aged six and older who weigh 45 kilograms or more.

Positive

Seeking Alpha

●

11 days ago

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and UZEDY are driving margin improvement, while partnerships and cost-cutting support a credible turnaround. Despite lingering legal and debt risks, Teva's low valuation offers a favorable risk/reward for ...

Neutral

Seeking Alpha

●

12 days ago

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Christopher J. Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Eliyahu Sharon Kalif - Executive VP & CFO Eric A.

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now